Want to see PCRX full AI Analyst Report?
PCRX Stock Chart & Stats
$25.53
$0.68(2.63%)
At close: 4:00 PM EDT
$25.53
$0.68(2.63%)
Day’s Range― - ―
52-Week Range$18.80 - $36.67
Previous CloseN/A
Volume164.31K
Average Volume (3M)1.90M
Market Cap
$1.45B
Enterprise Value$1.18B
Total Cash (Recent Filing)$251.03M
Total Debt (Recent Filing)$412.12M
Price to Earnings (P/E)103.2
Beta0.67
Next Earnings
Oct 29, 2026EPS Estimate
0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.35
Shares Outstanding39,861,885
10 Day Avg. Volume4,609,544
30 Day Avg. Volume1,904,860
Financial Highlights & Ratios
PEG Ratio-1.51
Price to Book (P/B)1.66
Price to Sales (P/S)1.59
P/FCF Ratio8.44
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue1.59
Enterprise Value/Gross Profit2.00
Enterprise Value/Ebitda10.31
Forecast
1Y Price Target
$34.79Price Target Upside36.25% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)2.9
Revenue Forecast (FY)$754.33M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationStrong operating and free cash flow, alongside cash conversion that generally tracks reported earnings, indicates Pacira is generating substantial underlying liquidity. This supports research investment, commercial execution, and balance-sheet resilience while reducing reliance on external financing over the next several quarters.
Expanded Payer AccessBroader reimbursement and formulary access can lower adoption barriers for EXPAREL and ZILRETTA across hospitals and clinical settings. Coverage reaching about 150 million lives provides a durable commercial platform, supporting procedure penetration and product demand beyond individual selling periods.
European Expansion PartnershipThe Molteni partnership extends Exparel into additional European markets while assigning regulatory, access, and commercialization work to an established pain-management partner. Pacira retains manufacturing economics and gains potential royalty revenue, creating a structural international growth channel from 2027.
Bears Say
Volatile ProfitabilityThe shift from profit to a sharp loss and back to only modest profitability shows that earnings quality remains inconsistent. Thin operating and net margins leave less protection against execution setbacks, making sustained revenue growth and cost discipline important for financial stability.
Higher Operating InvestmentHigher R&D and SG&A spending reflects investment in advancing pipeline programs and commercial operations, but it also raises the revenue threshold needed to expand earnings. If product growth does not outpace these costs, operating leverage and near-term profitability could remain constrained.
NOPAIN Reimbursement UncertaintyUncertainty around renewal of CMS NOPAIN reimbursement creates a longer-term access risk for Pacira’s non-opioid pain strategy. Delays or unfavorable rulemaking could affect provider economics and adoption, complicating planning for demand, reimbursement support, and future commercial expansion.
Pacira Pharmaceuticals News
PCRX FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was $18.80 and its highest was $36.66 in the past 12 months.
What is Pacira Pharmaceuticals’s market cap?
Pacira Pharmaceuticals’s market cap is $1.45B.
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is Oct 29, 2026 which is in 6 days.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on Aug 04, 2026. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.646 by $0.084.
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is 0.73.
How many shares outstanding does Pacira Pharmaceuticals have?
Pacira Pharmaceuticals has 39,861,885 shares outstanding.
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of $0.73 in its last earnings report, beating expectations of $0.646. Following the earnings report the stock price went down -9.957%.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Currently, no hedge funds are holding shares in PCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pacira Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$34.79 (36.25% Upside)
$34.79 (36.25% Upside)
Blogger Sentiment
Neutral
PCRX Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 21.3K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.98%
12-Months-Change
Fundamentals
Return on Equity
2.13%
Trailing 12-Months
Asset Growth
-19.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pacira Pharmaceuticals
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
PCRX Company Deck
PCRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted solid financial performance (6% revenue growth, robust adjusted EBITDA, strong cash position), meaningful commercial progress (major payer wins covering ~150M lives, EXPAREL and ZILRETTA momentum), important pipeline and manufacturing milestones (PCRX-201 manufacturing, multiple imminent readouts), and a strategic portfolio move (iovera divestiture with up to $140M consideration). Key challenges include softness in elective inpatient soft tissue procedures driven by macroeconomic factors, a decline in gross margin versus prior year, higher R&D and SG&A spend, and modest near-term moderation in EXPAREL volume growth. Overall, the positives — including clear payer wins, pipeline catalysts, cash generation, and strategic partnerships — outweigh the operational and margin headwinds.View all PCRX earnings summariesPCRX Stock 12 Month Forecast
Average Price Target
$34.79
▲(36.25% Upside)
Technical Analysis
Teva
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Amneal Pharmaceuticals
―
Ownership Overview
3.65% Insiders
24.57% Mutual Funds
1.42% Other Institutional Investors
34.02% Public Companies and
Individual Investors